Study Rationale:
Parkinson's disease affects people very differently. Some patients progress quickly and develop severe symptoms within a few years, while others remain stable for decades, even though they have the same diagnosis. This puzzling difference makes it hard for doctors to predict disease progression or choose the best treatments. Scientists have developed a promising test called a seed amplification assay that can detect abnormal alpha-synuclein protein clumps, which is currently the only validated biomarker for Parkinson's disease. However, we still don't understand what makes these protein clumps more or less harmful, or why test results vary so dramatically between patients.
Hypothesis:
We believe that other molecules naturally present in the body including fats, sugars, and modified proteins work together with alpha-synuclein protein clumps to make them more or less toxic to brain cells. These molecular partnerships create unique "fingerprints" that explain why people experience Parkinson's disease so differently, even when they have similar amounts of protein clumps.
Study Design:
We will analyze samples from brain tissue, spinal fluid, blood, and skin from patients with Parkinson's disease and healthy controls to identify molecules that affect alpha-synuclein toxicity. Using cutting-edge laboratory techniques including advanced microscopy and mass spectrometry, we will create a complete picture of the molecular environment in different parts of the body. We will then test our findings in lab-grown brain cells to confirm which factors truly matter for disease progression.
Impact on Diagnosis/Treatment of Parkinson’s disease:
This research could lead to better diagnostic tests that predict how quickly a person's Parkinson's will progress and which symptoms they're likely to develop. This would help doctors choose the most effective treatments for each patient and start therapy earlier.
Next Steps for Development:
If successful, we will validate our findings in larger patient groups worldwide and work with clinical teams to develop new diagnostic tests for hospitals and clinics. We also plan to identify molecular targets for personalized treatments.